Madison Small Cap Fund released its Q1 2026 investor letter, noting that while the fund slightly underperformed benchmarks, it maintained a preference for quality value stocks. The fund specifically highlighted Charles River Laboratories International (CRL) as a position that pulled back in the first quarter due to market fears regarding AI disruption within the healthcare sector.
Despite the pullback, the fund's strategy team argues that fears of AI replacing drug development are exaggerated. They believe AI tools will improve efficiency and program design times for contract research organizations (CROs) like CRL, leading to more viable drug candidates rather than reduced spending. Consequently, the fund remains enthusiastic about these investments and has selectively added to its positions in CRL.
The article notes that 43 hedge fund portfolios held CRL at the end of Q1 2026, down from 53 in the previous quarter. The fund manager suggests that while CRL is a solid investment, other AI stocks may offer higher returns and shorter time frames, though they do not view CRL as lacking promise.
📉 Shares pulled back in Q1 2026 due to healthcare sector underperformance.
💰 Fund cites market volatility and AI disruption fears as decline drivers.
🛡️ Managers dismiss AI fears, noting CRL's resources to capture AI value.
⚙️ AI adoption expected to shorten trials and boost clinical service demand.
📈 Fund selectively added positions despite recent share price pullback.
📉 Charles River Laboratories (CRL) saw its shares pull back in Q1 2026 as the Madison Small Cap Fund's healthcare sector underperformed.
💰 The fund attributes the decline to market volatility and fears that AI will disrupt drug development services.
🛡️ Fund managers argue that AI disruption fears are overexaggerated and that CROs like CRL have ample resources to capture value from AI tools.
⚙️ Implementation of AI is expected to shorten trial timelines, improve clinical submissions, and increase demand for clinical research services.
📈 Despite the pullback, the Madison Small Cap Fund has selectively added to its positions in Charles River Laboratories.
📊 CRL closed at $188.06 per share on June 11, 2026, with a market capitalization of $9.06 billion.
📉 Hedge fund holdings for CRL decreased from 53 portfolios in the previous quarter to 43 at the end of Q1 2026.
🤖 The fund believes larger CROs are better positioned than smaller peers to implement AI tools effectively.
🔍 The article references a separate report claiming other AI stocks have greater promise for delivering higher returns.
Bullish Signals
Fund remains enthusiastic despite recent price pullbacks.
AI implementation increases demand for clinical research services.
Larger CROs capture value from AI tools.
AI adoption shortens trial timelines and improves submissions.
Fund added positions in Q1 2026.
Risk Factors
Part of worst-performing Healthcare sector in Q1 2026.
Pullback due to AI disruption fears in drug services.
Hedge fund holdings dropped from 53 to 43.
Bullish Signals
The Madison Small Cap Fund remains enthusiastic about its investments in Charles River Laboratories despite recent price pullbacks.
Fund managers believe that AI implementation will lead to more viable drug candidates and an increase in demand for clinical research services.
Larger CROs like Charles River have ample resources to capture value from AI tools for both themselves and their clients.
AI adoption is expected to improve program design times, shorten trial timelines, and improve clinical submissions.
The fund has selectively added to its positions in Charles River Laboratories during the first quarter of 2026.
Risk Factors
Charles River Laboratories was part of the fund's worst-performing sector (Healthcare) in the first quarter of 2026.
The stock experienced a pullback driven by market fears that AI will disrupt drug development services.
Hedge fund interest in CRL declined, with portfolio holdings dropping from 53 to 43 between the previous quarter and Q1 2026.
Protesters gathered outside the Charles River Laboratories facility at 55 Union St. in Worcester on May 30 to demand an end to alleged beagle testing, citing national scrutiny and reports of animal abuse within the industry. The nondescript brick building houses one of the world's largest contract research companies, which declined to provide specific details about its testing operations in Worcester via email to local media. Government compliance documents indicate the facility housed approximately 264 dogs daily in 2023, though the breed was not listed; however, activists and protesters assert that beagles are the primary breed used due to their docile nature.
Stephen "Chip" Brown, a former sports reporter who organized the protest, criticized the company's refusal to acknowledge the dogs or disclose its activities, stating this secrecy is inconsistent with a proud organization. He argues that technological advancements, including AI-based models known as New Approach Methodologies (NAMs), make traditional beagle testing unnecessary. The FDA has also indicated it aims to reduce, refine, or replace animal testing requirements using such alternative methods. Brown highlighted recent high-profile cases of abuse and neglect in the industry, including violations at a Virginia breeder linked to beagle deaths in 2022 and Ridglan Farms in Wisconsin, which surrendered its breeding license after facing hundreds of citations for mistreatment.
Charles River Laboratories responded with a statement emphasizing that animal research is fundamental to understanding how to prevent and treat diseases, citing the development of every COVID-19 vaccine and treatments for cancer, diabetes, and rare diseases as examples. The company stated it is deeply committed to animal welfare and exceeding international standards for the care of research models under its stewardship, while also noting a commitment to reducing the number of animals used when possible. Activists have previously staged break-ins to rescue dogs from similar facilities, with one successful operation in March removing 22 dogs, and Brown has launched a petition seeking to stop testing on dogs in Worcester and put existing animals up for adoption.
🐕 Protesters gathered outside Charles River Labs demanding an end to alleged beagle testing.
📊 Documents show the facility housed ~264 dogs daily in 2023, though breeds were unlisted.
⚠️ Activists cite abuse reports and recent break-ins to rescue dogs from similar facilities.
🤖 FDA plans to reduce animal testing requirements using AI-based New Approach Methodologies.
💊 Charles River insists animal research is essential for drug safety and patient care.
🐕 Protesters gathered outside Charles River Laboratories in downtown Worcester on Saturday, May 30, demanding an end to alleged beagle testing.
📍 The demonstration took place at 55 Union St., a nondescript brick building housing one of the world's largest contract research companies.
🤐 Charles River declined to provide specific details about its testing operations in Worcester via email to the Telegram & Gazette.
📊 Government compliance documents indicate the facility housed approximately 264 dogs daily in 2023, though the breed was not listed.
🐶 The vast majority of laboratory test subjects are beagles due to their docile nature, despite the company not confirming or denying this specific claim.
💊 Charles River stated that global regulatory agencies require animal research before drugs can be evaluated in human clinical trials for patient safety.
🤖 The FDA announced in April that animal-testing requirements would be reduced, refined, or replaced using AI-based models called New Approach Methodologies (NAMs).
⚠️ Activists cited reports of abuse and neglect in the industry, including a Virginia breeder with violations leading to beagle deaths in 2022.
🔓 Ridglan Farms in Wisconsin recently surrendered its breeding license after facing hundreds of citations for mistreatment, including alleged eye surgeries without anesthesia.
💥 Incensed activists have staged multiple break-ins to rescue dogs, including a successful March operation removing 22 dogs and a failed April attempt involving tear gas.
📝 Stephen "Chip" Brown, a former reporter who started dogwalking in 2015, believes technological advancements make beagle testing unnecessary.
📜 A change.org petition authored by Brown regarding the issue had gathered about 2,300 signatures as of June 1.
🚗 Protesters received frequent honks from drivers on Major Taylor Boulevard during an unseasonably cold rain on May 30.
📺 WBZ TV's I-Team reported in 2015 that Charles River was the largest canine-testing company in Massachusetts with about 750 dogs.
🔒 The industry maintains secrecy regarding testing conditions and interviews, attributing this to safety concerns rather than hiding wrongdoing.
🙅♂️ Brown stated he is not looking to break into buildings but demands Charles River cease testing on dogs in Worcester immediately.
🐕 Brown also requested that all existing dogs at the facility be put up for adoption.
📧 Brown reached out to multiple Charles River employees via email seeking a dialogue but has not received a reply.
💉 Charles River emphasized that animal research is fundamental to developing treatments for diseases including cancer, diabetes, and rare diseases.
❤️ The company stated it is deeply committed to animal welfare and exceeding international standards for the care of research models.
Bullish Signals
Charles River emphasizes animal welfare exceeding international standards.
Animal research enabled every COVID-19 vaccine and treatments for cancer/diabetes.
Company leads project to develop New Approach Methodologies (NAMs).
FDA announced reduced, refined or replaced animal-testing using AI models.
Charles River employs approximately 750 dogs at its Worcester facility.
Risk Factors
Company cited secrecy for declining testing details despite protester claims.
Facility housed 264 dogs daily in 2023 with unlisted breeds.
Activists staged break-ins, rescuing 22 dogs and using tear gas.
Refused to acknowledge dogs or disclose activities under public pressure.
Petition against testing gathered 2,300 signatures by June 1.
Denied reporter access citing safety concerns protesters view as secrecy.
Bullish Signals
Charles River Laboratories emphasized its commitment to animal welfare and exceeding international standards for the care of research models under its stewardship.
The company stated that animal research is fundamental to understanding how to prevent and treat diseases, including the successful development of every COVID-19 vaccine as well as treatments for cancer, diabetes, and a myriad of rare diseases.
Charles River announced it is leading a project dedicated to developing New Approach Methodologies (NAMs) to reduce the number of animals used when possible.
The Food and Drug Administration in April announced its animal-testing requirement would be 'reduced, refined or potentially replaced' using AI-based models called 'New Approach Methodologies (NAMs).'
Charles River declined to provide specific information on its testing in Worcester, citing industry concerns about safety as a reason for secrecy regarding conditions.
The company is one of the world's largest contract research companies with a significant presence in Massachusetts, employing approximately 750 dogs at its facility as reported in 2015.
Risk Factors
The company declined to provide specific details about its testing operations in Worcester via email to local media, citing secrecy that protesters argue is inconsistent with a proud organization.
Government compliance documents indicate the facility housed approximately 264 dogs daily in 2023, though the breed was not listed, raising concerns about transparency regarding beagle usage.
Activists have previously staged break-ins to rescue dogs from similar facilities, including one successful operation in March removing 22 dogs and a failed April operation involving tear gas.
The company refused to acknowledge the dogs or disclose its activities despite public pressure, with protesters stating this secrecy is inconsistent with a proud organization.
A petition seeking to stop testing on dogs in Worcester had about 2,300 signatures as of June 1, indicating significant local opposition and potential reputational risk.
Charles River declined to allow reporters to see the conditions the dogs live in or conduct on-camera interviews, citing safety concerns which protesters interpret as a lack of transparency.
Charles River Laboratories (CRL) reported first-quarter revenue of $995.8 million, beating analyst estimates of $977.4 million with 1.2% year-on-year growth, while adjusted EPS reached $2.06 versus a consensus of $1.94, representing a 6% beat. The company highlighted that strategic divestitures, portfolio optimization, and cost-saving measures were central to margin improvement efforts, resulting in an operating margin of 12%, up from 7.6% in the prior year quarter. Management slightly raised its full-year adjusted EPS guidance to $11.05 at the midpoint, noting stable demand among global pharmaceutical customers despite varied activity in small and mid-sized biotech segments across regions.
During the earnings call, analysts focused on several key themes including seasonal demand trends, new approach methodologies (NAMs), proposal volume growth, margin sustainability, and future M&A priorities. CEO Birgit Girshick and CFO Glenn Coleman indicated high single-digit year-over-year growth for both pharma and biotech clients, with proposals rising sequentially for three consecutive quarters. They also addressed the impact of internalizing NHP supply on DSA margins, noting that benefits will materialize as high sourcing costs phase out, with further improvement expected in later quarters. The company plans to continue pursuing organic investment and selective acquisitions in strategic areas while monitoring the pace of margin expansion from recent divestitures and cost-saving initiatives.
📈 Q1 revenue beat estimates while organic revenue declined slightly.
💰 Adjusted EPS surpassed consensus and full-year guidance was raised.
🚀 Operating margins expanded significantly due to efficiency and divestitures.
Charles River Laboratories reported Q1 revenue of $995.8 million, beating analyst estimates by 1.9%.
Adjusted EPS of $2.06 exceeded expectations by 6%, demonstrating strong profitability.
The company raised its full-year Adjusted EPS guidance to $11.05 at the midpoint, signaling management confidence.
Operating margins expanded significantly to 12%, up from 7.6% in the same quarter last year.
Proposal volume growth is running at high single-digit rates year-over-year for both pharma and biotech clients.
Sequential proposal activity has risen for three consecutive quarters, indicating sustained demand momentum.
Management plans to continue pursuing organic investment and selective acquisitions in strategic areas.
Risk Factors
Organic revenue fell 1.5% year on year, indicating underlying weakness in core business growth despite overall revenue beating estimates.
The company navigated discrete margin headwinds, including higher costs in its research models and services segment.
CEO Birgit Girshick noted continued sluggishness in early-stage biotech demand across regions and segments.
Margin gains in the second half are expected to be driven by portfolio actions and cost initiatives rather than organic operational improvements.
Charles River Laboratories stock price dropped from $181.73 to $162.80 following the earnings report, reflecting market skepticism despite positive guidance.
Charles River Laboratories International (CRL) reported first-quarter 2026 financial results that align with or slightly exceed management's previous guidance while reaffirming its full-year outlook. The company reported total revenue of $996 million, a 1.2% increase year-over-year on a reported basis, though organic revenue declined by 1.5%, consistent with prior expectations of a low single-digit decline. Non-GAAP earnings per share decreased 12% to $2.06, and the non-GAAP operating margin fell 280 basis points to 16.3%. Management attributes these declines to specific factors including lower revenue from third-party non-human primate sources, timing of stock compensation expenses related to the CEO transition, and increased sourcing costs within the Discovery and Safety Assessment segment.
The quarter featured mixed performance across business segments, with the Manufacturing division showing organic growth of 2.9% and an operating margin improvement to 25.9%, driven by gains in Microbial Solutions. Conversely, the Research Models and Services segment saw a 5.5% organic revenue drop due to lower sales of research models, while the Discovery and Safety Assessment unit posted a 1.4% organic decline. New CEO Birgit Girshick, who took office around the time of the earnings call, introduced a refreshed strategic framework titled "Pathway to Purpose," focusing on operational modernization and portfolio strengthening. The company completed the divestiture of its CDMO and Cell Solutions businesses and plans to sell certain European discovery sites later in May to refine its portfolio and improve margins.
Guidance for the full year 2026 remains intact with projected organic revenue decline between 0.5% and 1.5%, and non-GAAP EPS of $10.80 to $11.30, representing a 5% to 10% growth over 2025 levels. Management expects operating margin expansion of approximately 120 to 150 basis points throughout the year, with significant improvement anticipated in the second half due to completed acquisitions, divestitures, and cost savings. Charles River also repurchased approximately $200 million in shares during the quarter under a $1 billion authorization, maintaining net leverage at 2.6 times. The company plans to provide further details on its strategy at an upcoming Investor Day in September.
📊 Q1 revenue rose 1.2% YoY, but margins contracted 280 bps due to transition costs.
🔄 Company reaffirmed full-year guidance, expecting low single-digit organic revenue decline and EPS up in Q2.
🏷️ Leadership closed CDMO divestiture and plans further European site sales to improve portfolio health.
📅 Charles River Laboratories (CRL) reported first-quarter 2026 results that slightly outperformed its prior outlook under new CEO Birgit Girshick.
🎯 CEO Birgit Girshick introduced a refreshed strategic framework titled "Pathway to Purpose" focused on modernization, portfolio strength, and improved profitability.
💰 Reported Q1 revenue reached $996 million, a 1.2% year-over-year increase, while organic revenue declined by 1.5%.
📉 Non-GAAP operating margins contracted 280 basis points to 16.3%, driven by lower NHP third-party revenue and higher sourcing costs.
🔧 The CFO attributed the margin decline to CEO transition stock compensation expenses and unfavorable timing of NHP shipments in specific segments.
🔄 The company repurchased approximately $200 million in shares during the quarter under its existing $1 billion authorization program.
📊 Discovery and Safety Assessment segment revenue fell 1.4% organically, with discovery services down partly due to prior site consolidation.
🦮 Research Models and Services revenue dropped 5.5% organically, pressured by lower North American small model volumes despite solid growth in China.
🧪 Manufacturing segment showed strength with organic revenue up 2.9%, driven by growth in the Microbial Solutions business.
📈 Q1 EPS declined 12% to $2.06 on a non-GAAP basis but exceeded guidance for the high-teens decline range.
🤝 Charles River reaffirmed its full-year 2026 guidance, expecting organic revenue decline of 0.5% to 1.5% and EPS between $10.80 and $11.30.
💸 Management noted a 50 basis point reduction in reported revenue outlook due to strengthening U.S. dollar foreign exchange headwinds.
🗓️ The company expects operating margin expansion of 120 to 150 basis points in 2026, with the majority occurring in the second half of the year.
🏷️ For Q2, reported revenue is expected to decline at a mid- to high-single-digit rate primarily due to ongoing divestitures.
📉 Second-quarter organic revenue is projected to decline at a low-single-digit rate, consistent with the first quarter performance.
💹 Q2 EPS is forecasted to increase by at least 30% sequentially from the first-quarter level of $2.06.
💼 Charles River completed the divestiture of its CDMO and Cell Solutions businesses on May 6 to refine its portfolio toward core competencies.
🏭 The company plans to complete the sale of certain European discovery sites later in May to further improve operating margins.
🇰🇭 Charles River acquired assets from K.F. Cambodia earlier this year to strengthen and secure its NHP supply chain for safety assessment operations.
Bullish Signals
Management reaffirmed 2026 full-year organic revenue and earnings guidance.
Manufacturing organic revenue rose 2.9% with margins expanding to 25.9%.
Charles River repurchased $200 million of shares under $1B authorization.
Company completed May 6 divestiture of CDMO and Cell Solutions businesses.
Discovery and Safety Assessment revenue dropped 1.4% organically.
Research Models and Services revenue decreased 5.5% organically.
Full-year 2026 outlook revised with 4.0% to 5.5% decline.
H2 revenue expected to drop mid- to high-single digits.
NHP segment faces higher sourcing costs.
Bullish Signals
Management reaffirmed full-year organic revenue and non-GAAP earnings guidance for 2026, demonstrating confidence in the strategic direction under new CEO Birgit Girshick.
Manufacturing segment reported positive growth with organic revenue up 2.9% and operating margin expanding 280 basis points to 25.9%, driven by strong performance in Microbial Solutions businesses like Endosafe and Celsis.
Charles River repurchased approximately $200 million of shares during the quarter, strengthening balance sheet under a $1 billion authorization approved last October.
Management expects operating margin expansion of about 120 to 150 basis points in 2026, with second-half operating margins projected to be more than 500 basis points higher than the first half.
Second-quarter earnings per share are expected to increase at least 30% sequentially from Q1, signaling strong profitability improvements despite modest revenue declines.
The company successfully completed the divestiture of its CDMO and Cell Solutions businesses on May 6, refining its portfolio around core competencies to improve future margins.
Charles River strengthened its NHP supply chain by acquiring assets from K.F. Cambodia for safety assessment operations, supported by its earlier controlling stake acquisition in Noveprim.
EPS exceeded management's prior outlook for a high-teens decline due to better-than-expected operating performance in the Manufacturing and Research Models and Services segments.
Risk Factors
First-quarter revenue declined 1.5% on an organic basis, consistent with prior forecasts of a low single-digit decline.
Non-GAAP operating margins contracted 280 basis points year over year to 16.3%, driven by higher NHP sourcing costs and unfavorable revenue mix.
Non-GAAP earnings per share fell 12% to $2.06, signaling significant pressure on profitability despite management guidance being met.
Discovery and Safety Assessment segment revenue dropped 1.4% organically due to lower discovery services and higher study-related direct costs.
Research Models and Services revenue decreased 5.5% organically, pressured by lower North American small model volume and unfavorable NHP shipment timing.
Charles River reduced its full-year 2026 revenue outlook by an additional 50 basis points to a decline of 4.0% to 5.5% due to a strengthening U.S. dollar.
Second-quarter reported revenue is expected to decline at a mid- to high-single-digit rate, primarily driven by completed divestitures including the CDMO and Cell Solutions businesses sold on May 6.
Non-human primate (NHP) segment faces specific headwinds from increased sourcing costs and timing mismatches affecting both manufacturing and research segments.
Morgan Stanley analyst Kallum Titchmarsh maintained a Hold rating on Charles River Laboratories (CRL) following the company's recent earnings release, setting a price target of $168.46. This action comes amidst mixed signals for the biopharmaceutical services company, as William Blair reiterated its Buy rating and Mizuho Securities also issued a Hold via analyst Ann Hynes on May 8. The article highlights that Charles River Labs reported quarterly revenue of $995.83 million for the quarter ending March 28, showing modest growth from last year's $984.17 million, but notably posted a GAAP net loss of $14.84 million compared to a net profit of $25.47 million in the same period prior year. Analyst Kallum Titchmarsh covers the healthcare sector and has historically maintained an average return of -0.8% with a 34.29% success rate according to TipRanks data. The report serves as an update on the shifting analyst sentiment regarding Charles River Labs, contrasting the new Hold rating from Morgan Stanley with the continued optimism from William Blair which previously maintained a $235 price target.
📉 Analysts maintain mixed ratings with most holding Charles River Labs at current levels.
💰 Revenue grew slightly to $995.83M but GAAP net loss widened to $14.84M.
🧪 The company faces cyber risks and varying price targets from different analysts.
🔍 Morgan Stanley analyst Kallum Titchmarsh maintained a Hold rating on Charles River Labs (CRL) with a price target of $168.46.
📉 TipRanks data indicates analyst Titchmarsh has an average return of -0.8% and a 34.29% success rate covering the Healthcare sector.
➕ Mizuho Securities’s Ann Hynes also issued a Hold rating on CRL in a report from May 8, adding to recent cautious sentiment.
🟢 Conversely, William Blair reiterated a Buy rating on Charles River Labs, offering a contrasting positive outlook to the other analysts.
💰 For the quarter ending March 28, Charles River reported revenue of $995.83 million, showing slight growth from $984.17 million last year.
📉 The company recorded a GAAP net loss of $14.84 million this quarter, down from a net profit of $25.47 million in the prior-year period.
🧪 Charles River operates within the Healthcare sector and focuses on services such as those offered by West Pharmaceutical Services and Stevanato Group.
📰 Related news mentions share approval for a new incentive plan and 'continued momentum' in its digital pathology platform.
📈 Other analysts, such as Evercore ISI, recently raised CRL's price target to $220, highlighting varying market opinions on the stock.
⚠️ Potential risks include cyber threats like AI-enabled attacks and third-party risks mentioned in recent coverage of the company.
This article from Simply Wall St analyzes the valuation of Charles River Laboratories International (CRL) following a recent price rebound, questioning whether the current share price of approximately US$181.68 represents fair value or a mispricing opportunity. The stock has risen 8.8% over the last week but remains down 10.2% year-to-date and 43.4% over the past five years, while gaining 28.5% in the last 12 months alone. The analysis begins with a Discounted Cash Flow (DCF) model using a two-stage free cash flow to equity approach, which projects intrinsic value at US$140.41 per share based on free cash flow estimates extending to 2035. Under this scenario, the current market price suggests the stock is overvalued by roughly 29.4%.
The report then shifts to Price-to-Sales (P/S) metrics, noting that CRL currently trades at a P/S ratio of 2.23x, which is below the Life Sciences industry average of 3.50x and the peer group average of 3.43x. The article introduces Simply Wall St's proprietary "Fair Ratio" model, which calculates a fair P/S of 2.87x after adjusting for growth, margins, and risk. Since the stock is trading below this proprietary fair ratio, it suggests CRL may actually be undervalued when compared to its specific operational profile rather than raw industry averages.
Finally, the article introduces the concept of "Narratives" to provide a broader context for valuation beyond single-point estimates, presenting three different community-driven outlooks with fair values ranging from US$135.89 to US$261.63 based on varying assumptions about revenue growth and profit margins. The piece concludes by previewing the company's "Bull Case" narrative, which sets a fair value of around US$313.61, implying the stock is undervalued by approximately 42% at current prices. This bullish view specifically highlights the strategic importance of CRL acquiring K.F. in Cambodia to secure long-term access to non-human primates, a resource currently considered constrained for preclinical research purposes.
📈 Stock rebounded 28.5% YTD while trading 43.4% below its five-year high.
💰 DCF model values shares at $140.41, suggesting current price is ~29% overvalued.
🎯 Bull case narrative projects fair value of $313.61 assuming strong growth and acquisitions.
📈 Charles River Laboratories International (CRL) stock has rebounded 8.8% over the last 7 days and 28.5% year-to-date despite a broader long-term decline of 43.4% over five years.
💰 A Discounted Cash Flow (DCF) model suggests CRL is currently overvalued by approximately 29.4%, with an estimated intrinsic value of $140.41 versus the current price of around $181.68.
📊 Based on a Price-to-Sales (P/S) ratio analysis, CRL trades at 2.23x, which is below both its peer group average of 3.43x and industry average of 3.50x.
🎯 Simply Wall St's proprietary "Fair Ratio" framework values the stock at 2.87x P/S, indicating it may be trading below its specific fair valuation when adjusted for growth and risk.
🧠 The article introduces "Narratives" as a method to compare investor expectations by modeling future revenue, earnings, margins, and fair value scenarios ranging from $135.89 to $261.63.
🐂 A bullish case narrative projects a fair value of roughly $313.61, implying the stock is undervalued by about 42.1% at current levels if high growth assumptions are met.
🧬 The bull case specifically highlights potential strategic advantages from acquiring K.F. in Cambodia to secure long-term access to non-human primates for preclinical research.
⚖️ DCF analysis relies on a two-stage free cash flow model projecting $368.5 million in the latest year and extending forecasts up to $444.99 million by 2035.
📉 The valuation gap between the current market price and intrinsic value suggests CRL may face short-term headwinds despite recent positive momentum.
🏭 Investors are encouraged to evaluate whether the stock's narrative aligns with their own expectations regarding future revenue growth and profit margins before deciding on a position.
Bullish Signals
Charles River delivered 8.8% return in 7 days.
Free Cash Flow grows to $379.7M in 2026.
Analysts rate stock ~42.1% undervalued at US$313.61.
Bull case assumes robust 9.0% revenue growth.
Company secures primates via Cambodia strategic acquisition.
Risk Factors
Stock overvalued by 29.4% vs DCF intrinsic value of US$140.41.
Poor long-term returns: 5-year decline of 43.4% and 3-year drop of 7.2%.
P/S ratio of 2.23x trails industry average of 3.50x.
Community narratives imply substantial downside risk starting at US$135.89.
Modest FCF growth may not justify current high pricing.
Bullish Signals
Charles River Laboratories delivered strong recent performance with an 8.8% return over the last 7 days and 28.5% year-to-date.
The company projects Free Cash Flow growth to $379.7 million in 2026 and $402.7 million in 2027, demonstrating upward trajectory.
A leading community narrative identifies the stock as roughly 42.1% undervalued compared to a fair value of about US$313.61 per share.
The Bull Case assumes robust revenue growth of 9.0%, which is significantly higher than the current market expectations.
Charles River Laboratories is pursuing a strategic acquisition of K.F. in Cambodia to secure long-term access to non-human primates, a constrained resource critical for preclinical research.
Risk Factors
The stock is trading at US$181.68, while the Discounted Cash Flow model estimates an intrinsic value of only US$140.41, suggesting the shares are overvalued by 29.4%.
Historical performance has been poor, with a 5-year return decline of 43.4% and a 3-year decline of 7.2%, despite recent short-term gains.
The current Price-to-Sales ratio of 2.23x is significantly below both the Life Sciences industry average of 3.50x and the peer group average of 3.43x, indicating weaker relative valuation support.
Community narratives provide a range of fair values starting as low as US$135.89, implying substantial downside risk if lower growth assumptions materialize.
Future revenue growth assumptions vary widely among different valuations, with some scenarios projecting only 3.1% annual growth by 2029.
Analysts project Free Cash Flow growth from $368.5 million in the last twelve months to $402.7 million in 2026, a modest expansion that may not fully justify current pricing.
Charles River Laboratories International (CRL) stock has been downgraded to a 'Sell' rating following a 57% rally over the past year, which analysts argue has outpaced underlying fundamentals. While the company reported stabilization in Q1, organic revenue actually declined by 1.5%, and profit margins have compressed, signaling muted near-term growth prospects. Despite the stock trading at a discount to its historical average with a forward P/E of 17.5x, the current valuation is viewed as unwarranted given the limited growth trajectory and specific risks on the horizon.
The primary catalyst for the downgrade includes looming long-term threats from artificial intelligence-driven disruption in laboratory services and persistent regulatory uncertainty regarding potential bans on animal testing. Although management maintains its fiscal 2026 EPS guidance range of $10.80 to $11.30, the analyst advises investors that discipline around valuation is crucial at these levels. Consequently, the recommendation shifts from a "Hold" or "Buy" stance to taking profits now that the stock has significantly appreciated, citing the lack of robust growth to justify such a steep gain over twelve months.
⚠️ Long-term risks persist from potential AI disruption and FDA regulatory uncertainties.
💵 Management expects 2026 EPS between $10.80 and $11.30 at ~17.5x forward earnings.
🛑 Analysts advise taking profits due to valuation discipline amid limited growth visibility.
📉 Charles River Laboratories (CRL) is downgraded to 'Sell' despite a 57% share price rally over the past year that has outpaced underlying fundamentals.
💰 The company reported Q1 organic revenue decline of 1.5% and margin compression, indicating muted near-term growth.
⚠️ Long-term risks include potential AI-driven business disruption and regulatory uncertainties regarding animal testing bans by the FDA.
💵 Management maintains 2026 EPS guidance between $10.80 and $11.30 for the year.
📊 Current valuation stands at approximately 17.5x forward earnings, which is a discount to historical levels but not considered cheap.
🛑 Analyst recommendation suggests investors should take profits due to warranted valuation discipline in the face of limited growth visibility.
🏥 CRL has previously faced significant headwinds from fears about FDA policies banning animal testing, though these impacts are now stabilizing.
🧑💻 The article emphasizes contrarian investment strategies and macro views but includes standard disclosures regarding analyst positions.
⚖️ Seeking Alpha notes that past performance does not guarantee future results and advises investors to determine suitability for themselves.
📝 The content expresses the specific opinion of an individual author rather than reflecting the official stance of Seeking Alpha as a whole.
2026 EPS guidance stable between $10.80 and $11.30.
Valuation trades at 17.5x forward earnings below historical averages.
Risk Factors
Rally driven by speculation with weak fundamentals.
Organic revenue dropped 1.5% in Q1.
Profit margins compressed due to cost pressures.
Stock trades at expensive 17.5x forward earnings.
AI disruption threatens long-term growth prospects.
FDA bans on animal testing pose ongoing risks.
Analysts recommend taking profits given limited upside.
Bullish Signals
Charles River Laboratories shares have rallied 57% over the past year, significantly outperforming its peers despite recent analyst downgrades.
The company maintains a stable 2026 EPS guidance range of $10.80–$11.30, providing a clear earnings target for investors.
Current trading valuation at 17.5x forward earnings represents a discount to historical averages, suggesting potential value despite the 'Sell' rating.
Risk Factors
Charles River Laboratories stock has rallied 57% in the past year but this outperformance is attributed to speculation rather than improving fundamentals, suggesting the rally may be unsupportable.
Organic revenue declined 1.5% in Q1, indicating underlying business weakness despite overall stabilization efforts.
Profit margins compressed during the quarter, signaling operational inefficiencies or increased cost pressures.
The company maintains significant valuation risk, trading at 17.5x forward earnings which is considered insufficiently cheap despite a historical discount.
Long-term growth prospects are muted due to potential AI-driven disruption in laboratory testing and services.
Persistent regulatory headwinds regarding the FDA and potential bans on animal testing continue to pose a threat to core business operations.
Analysts recommend investors take profits, indicating limited upside remaining given current limited growth outlook.
Charles River Laboratories International, Inc. (CRL) reported quarterly earnings of $2.06 per share for the quarter ended March 2026, surpassing the Zacks Consensus Estimate of $1.96 by 5.24%. This compares to adjusted earnings of $2.34 per share in the same quarter a year ago. Revenues reached $995.83 million, exceeding estimates by 2.55%, marking the fourth consecutive quarter where both EPS and revenue beat consensus. However, current consensus EPS for the coming quarter is estimated at $2.68 on $1 billion in revenues, while the fiscal year consensus stands at $10.97 on $3.97 billion in revenues.
Despite the strong recent performance, CRL shares have underperformed the broader market over the past year, dropping about 8.9% versus an S&P 500 gain of 7.6%. The article notes that the stock's immediate future performance is largely dependent on management commentary and upcoming estimates revisions. Based on mixed estimate revisions ahead of the report, the company currently holds a Zacks Rank #3 (Hold), suggesting shares are expected to perform in line with the market. The industry outlook is positive, with the Medical Services sector ranked in the top 37% out of 250+ industries, which historically correlates with significant outperformance compared to the bottom half of industries.
The text also briefly mentions a peer company, Sonida Senior Living (SNDA), noting that it has not yet released results for the quarter ended March 2026 but is expected to report on May 11 with an anticipated loss of $1.67 per share and revenues of $87.94 million, up 9.5% year-over-year.
📈 Q1 EPS beat estimates by 5.24%, driven by non-recurring adjustments.
💰 Revenue surpassed consensus, marking a fourth consecutive quarter of beats.
📈 Charles River Laboratories reported Q1 earnings of $2.06 per share, beating the consensus estimate of $1.96.
📉 Adjusted quarterly earnings of $2.34 compare to a year-ago figure of $2.34, with the beat driven by non-recurring items adjustments.
🎯 The company delivered an earnings surprise of +5.24% in the current quarter and has surpassed EPS estimates four times over the last four quarters.
💰 Revenue for the quarter ended March 2026 reached $995.83 million, surpassing the consensus estimate by 2.55%.
📊 Charles River has topped revenue estimates for four consecutive quarters, with year-over-year revenue growth of roughly 1.2%.
📉 Shares have underperformed the S&P 500 significantly in 2026 so far, losing about 8.9% versus a 7.6% market gain.
🔮 The company currently holds a Zacks Rank #3 (Hold), indicating expectations that shares will perform in line with the near future.
🏥 Charles River operates within the Medical Services industry, which is ranked in the top 37% among all tracked industries.
🤖 Management commentary on the earnings call will be crucial for determining the sustainability of recent price movements.
👀 Analysts expect consensus EPS to reach $2.68 and revenues of $1 billion for the coming quarter based on current estimates.
🔍 Earnings estimate revisions are a key indicator tracking stock performance, with Zacks research highlighting their strong correlation.
💼 Competitor Sonida Senior Living is scheduled to report results on May 11 with an expected quarterly loss of $1.67 per share.
📈 Sonida expects revenues of $87.94 million for the upcoming quarter, representing a 9.5% increase from the year-ago period.
🛑 Investors are advised to monitor industry-level trends as they can materially impact Charles River's stock performance.
Bullish Signals
Reported earnings of $2.06/share, beating estimates by +5.24%.
Quarterly revenues reached $995.83M, up 1.2% year-over-year.
Surpassed EPS estimates four times over the last four quarters.
Part of top 37% Medical Services industry sector.
Shares gained about 48% over the last year.
Risk Factors
Shares lost 8.9% YTD, underperforming S&P 500.
Estimates mixed; Zacks Rank #3 suggests mere performance.
EPS declined to $2.06 from $2.34 prior year.
Peer Sonida (SNDA) faces loss of $1.67.
Bullish Signals
Charles River Laboratories reported earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.96 per share by +5.24%.
The company posted revenues of $995.83 million for the quarter ended March 2026, surpassing the consensus estimate by 2.55% and representing growth compared to the year-ago revenue of $984.17 million.
Charles River has surpassed consensus EPS estimates four times over the last four quarters, demonstrating consistent performance above expectations.
The company is part of the Medical Services industry, which currently ranks in the top 37% of Zacks industries and historically outperforms by a factor of more than 2 to 1.
Over the long run, Charles River shares have gained about 48% over the last year, demonstrating strong long-term resilience despite recent short-term fluctuations.
Risk Factors
Charles River Laboratories shares have lost approximately 8.9% year-to-date, significantly underperforming the S&P 500's gain of 7.6%.
Ahead of the earnings release, estimate revisions for Charles River were mixed, resulting in a Zacks Rank #3 (Hold) which suggests the stock is expected to merely perform in line with the market rather than outperform.
Earnings per share of $2.06 represent a decline from $2.34 per share recorded in the same quarter one year ago.
The industry context presents uncertainty, as peer company Sonida Senior Living (SNDA) is expected to report a quarterly loss of $1.67 per share representing a -116.9% year-over-year deterioration.
Charles River Laboratories International (NYSE: CRL) reported first-quarter 2026 financial results that reflected a transition period following recent strategic divestitures and executive changes. Total revenue for the quarter was $995.8 million, representing a 1.2% increase year-over-year to Q1 2025. However, this growth masked underlying organic decline; after adjusting for foreign currency translation effects which boosted reported revenue by 2.8%, and excluding a small revenue reduction due to a divestiture, organic revenue fell by 1.5%. This overall contraction was driven primarily by declines in the Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments, which were only partially offset by growth in the Manufacturing Solutions segment.
GAAP earnings per share showed a loss of $0.30 due to a significant one-time charge of $118 million related to a loss on assets held for sale stemming from the company's divestiture of its CDMO and Cell Solutions businesses. Despite this, management highlighted that excluding these non-recurring items, the business delivered solid operational performance in key areas. Specifically, the Manufacturing segment saw an 6.8% year-over-year revenue increase to $190.5 million, driven by growth in Microbial Solutions, though the loss of the CDMO business within that segment was notable as the company shifts focus. The RMS segment, which accounts for a large portion of the business, reported organic revenue decreases, particularly in North America for both small and large research models, although higher revenue in China provided some relief.
On the profitability front, GAAP operating margins improved to 12.0% compared to 7.6% in the prior year quarter, primarily because lower accelerated amortization expenses from the divested CDMO client relationships reduced costs significantly. However, on a non-GAAP basis, which management prefers for evaluating ongoing operations, the operating margin decreased to 16.3% from 19.1%. This decline was attributed to higher direct study-related costs in the DSA segment related to large-model sourcing, an unfavorable revenue mix in the RMS segment, and increased stock-based compensation tied to executive transitions. CEO Birgit Girshick reaffirmed the company's guidance for the full year, citing strong bookings in the first quarter and confidence in the current demand environment, particularly within the DSA sector, while emphasizing a long-term strategy focused on modernizing the portfolio and enhancing client experience.
Looking forward, Charles River Laboratories is moving into what leadership describes as its next chapter of growth following the completion of major restructuring activities. The company has repurchased $200 million of its common stock during the first quarter of 2026, demonstrating a commitment to returning capital to shareholders. While immediate earnings per share on a non-GAAP basis decreased by 12.0% year-over-year to $2.06 due to the aforementioned cost pressures and margin compression, management maintains confidence in their trajectory for improving results over the course of the year. The successful execution of the divestiture strategy and the stabilization of organic revenue flows remain central to their long-term value creation plan as they pivot away from legacy CDMO operations toward a more focused scientific services portfolio.
📈 Q1 2026 revenue reached $995.8M, up 1.2% driven by Manufacturing growth.
⚠️ GAAP loss of $0.30 includes an $118M charge for CDMO divestiture assets.
💵 Non-GAAP EPS hit $2.06 while the company repurchased $200M in stock.
Charles River Laboratories International Inc. reported first-quarter earnings that, while showing a net loss of $14.8 million or 30 cents per share, beat Wall Street expectations due to strong adjusted performance and revenue growth. The company posted adjusted earnings of $2.06 per share against an analyst consensus estimate of $1.96, driven by underlying operational strength despite the headline loss likely stemming from non-operating costs or tax impacts not detailed in this brief snapshot. Revenue reached $995.8 million, surpassing the average analyst forecast of $971.1 million, which indicates healthy demand for its medical research equipment and services. This positive revenue performance suggests that core business segments are expanding or maintaining market share effectively during the quarter.
Looking ahead, Charles River guidance reflects a cautious but optimistic outlook for the remainder of the year, with full-year earnings expected to range between $10.80 and $11.30 per share. The company’s ability to generate revenue above forecasts while managing a net loss suggests management is navigating short-term headwinds without compromising long-term growth trajectories. Investors may view this as a temporary dip in profitability rather than a structural decline, particularly given that the beat on adjusted metrics often signals confidence in future cash flow generation. The automated nature of the report confirms these figures are derived from standard financial data feeds, ensuring consistency with other market reports for ticker CRL. Overall, the earnings release reinforces Charles River’s position as a resilient performer in the life sciences outsourcing sector, even when headline EPS dips due to one-time items or strategic investments.
📉 Q1 saw a $14.8M loss but adjusted earnings hit $2.06/share.
📈 Revenue reached $995.8M, beating analyst forecasts by over $24M.
🚀 Management raised full-year earnings guidance to $10.80–$11.30 per share.
📉 Charles River Laboratories reported a quarterly loss of $14.8 million in Q1, translating to a 30-cent loss per share.
💰 Despite the nominal loss, adjusted earnings for one-time items reached $2.06 per share.
📈 The results exceeded Wall Street expectations, with analysts expecting $1.96 per share versus the reported $2.06.
🚀 Management raised full-year earnings guidance to a range of $10.80 to $11.30 per share.
Bullish Signals
CRL revenue hit $995.8M, beating forecasts.
Adjusted EPS reached $2.06, surpassing estimates.
Strong adjusted metrics show underlying resilience.
Risk Factors
Charles River lost $14.8M in Q1 despite adjusted earnings guidance.
Company reported a 30-cent per-share loss, showing profitability issues.
Bullish Signals
Charles River Laboratories International Inc. (CRL) posted revenue of $995.8 million in the first quarter, exceeding Street forecasts which were estimated at $971.1 million by six analysts surveyed by Zacks Investment Research.
The company's adjusted earnings per share reached $2.06, surpassing Wall Street expectations of $1.96 per share as predicted by eight analysts surveyed by Zacks.
Despite a reported loss on a GAAP basis, the strong performance in adjusted metrics and revenue demonstrates underlying business strength and operational resilience.
Risk Factors
Charles River Laboratories International Inc. reported a loss of $14.8 million in the first quarter, a significant negative financial metric despite adjusted earnings guidance.
The company recorded a per-share loss of 30 cents for the quarter, indicating an underlying profitability challenge even before one-time adjustments.
Charles River Laboratories International, Inc. (CRL) is set to release its first-quarter earnings report with Wall Street analysts forecasting quarterly EPS of $1.96 per share, which represents a 16.2% decline from the prior year. Revenue is expected to be approximately $971.06 million, marking a slight decrease of 1.3% compared to the same period last year. Over the past 30 days, the consensus EPS estimate has been revised downward by 4.6%, reflecting analysts' reassessment of initial projections as a key factor for predicting short-term stock price movements.
Analyst forecasts break down CRL’s performance across its three primary business segments: Research Models and Services, Manufacturing Solutions, and Discovery and Safety Assessment. Revenue from Research Models and Services is projected to be $208.44 million, down 2.2% year-over-year. In contrast, Manufacturing Solutions revenue is expected to reach $187.36 million, a 5% increase, while Discovery and Safety Assessment revenue is forecast at $587.28 million, essentially flat with a -0.9% change. Operating income figures vary by segment and measurement; for instance, Non-GAAP operating income for Manufacturing Solutions is estimated at $45.39 million, compared to $41.17 million in the prior year, whereas Discovery and Safety Assessment Non-GAAP operating income is projected at $129.35 million versus $141.70 million last year.
Recent stock performance shows CRL shares gaining 9.4% over the past month, slightly underperforming the Zacks S&P 500 composite which rose 10.3%. The stock currently holds a Zacks Rank of #3 (Hold), suggesting potential alignment with broader market trends in the near future. Investors are urged to monitor earnings revisions and segment-specific metrics as these often drive investor reaction more than headline estimates alone, particularly given the recent downward adjustment in EPS expectations.
📉 Analysts forecast Q1 EPS of $1.96, representing a 16.2% year-over-year decline.
📦 Revenue is expected at $971.06M with Discovery and Safety Assessment driving most growth.
⚙️ Manufacturing Solutions leads growth (+5%) while Research Models services sees revenue drops.
💰 Operating income projections show mixed results across the company's three divisions.
📉 Analysts predict Charles River (CRL) Q1 earnings of $1.96 per share, marking a 16.2% decline compared to the same quarter last year.
📊 Revenue is forecasted at $971.06 million, reflecting a slight year-over-year decrease of 1.3%.
📉 Over the past 30 days, the consensus EPS estimate has been revised downward by 4.6%, indicating analysts' reassessment of initial projections.
🔍 Earnings estimates show a strong correlation with short-term stock price movements according to empirical studies.
🧪 Revenue from Research Models and Services is expected to reach $208.44 million, down 2.2% year-over-year.
⚙️ Manufacturing Solutions revenue is projected at $187.36 million, representing a 5% increase from the prior-year quarter.
🛡️ Discovery and Safety Assessment revenue is estimated at $587.28 million, with a minor decline of 0.9% from last year.
💰 Non-GAAP operating income for Manufacturing Solutions is forecasted at $45.39 million compared to $41.17 million previously.
🔬 Non-GAAP operating income for Discovery and Safety Assessment is predicted at $129.35 million versus $141.70 million a year ago.
📦 Research Models and Services non-GAAP operating income is estimated at $49.93 million compared to $57.73 million last year.
🧬 Discovery and Safety Assessment operating income (GAAP) is projected at $104.54 million, up from $93.95 million the prior year.
📐 Research Models and Services GAAP operating income stands at an estimated $36.87 million versus $43.61 million last year.
📈 CRL shares have returned +9.4% over the past month, trailing the Zacks S&P 500 composite's +10.3% gain.
🏷️ The stock currently carries a Zacks Rank #3 (Hold), suggesting performance may align with the overall market.
📊 Investors should monitor key metrics alongside headline estimates to fully assess the upcoming earnings report.
Bullish Signals
Revenue from Manufacturing Solutions expected to reach $187.36 million.
Operating income for Discovery and Safety Assessment projected at $104.54 million.
Shares up 9.4% this month, slightly under S&P 500's 10.3% gain.
Company holds Zacks Rank #3 (Hold).
Risk Factors
EPS estimates revised down 4.6% recently.
Projected revenue drops 1.3% year-over-year.
Research segment expected to contract 2.2%.
Operating income forecast shows negative growth.
Earnings predicted at $1.96, down 16.2%.
Stock underperformed S&P 500 by 0.9%.
Analysts maintain Zacks Rank #3 Hold rating.
Bullish Signals
Analysts forecast that revenue from 'Manufacturing Solutions' will reach $187.36 million, representing a positive 5% year-over-year increase compared to the prior quarter.
The company's shares have returned +9.4% over the past month, though this outperformed less than the Zacks S&P 500 composite's +10.3% change, indicating reasonable performance relative to the broader market.
Operating income for 'Discovery and Safety Assessment' is projected to reach $104.54 million, which compares favorably against the year-ago value of $93.95 million.
Charles River currently carries a Zacks Rank #3 (Hold), suggesting performance that may align with the overall market in the near future.
Risk Factors
Analyst consensus EPS estimates have been revised downward by 4.6% over the past 30 days, signaling growing pessimism about earnings potential ahead of the quarterly report.
Projected total revenue is forecasted to decline 1.3% year-over-year to $971.06 million, with the Research Models and Services segment specifically expected to contract by 2.2%.
Operating income forecasts show negative growth across multiple segments: Discovery and Safety Assessment (down 0.9%), Research Models and Services (down 14.3%), and Manufacturing Solutions (flat at $45.39 million vs previous year).
The company is predicted to post earnings of $1.96 per share, reflecting an annual decline of 16.2%, indicating potential significant pressure on profitability.
Charles River stock has underperformed the broader market recently, gaining only +9.4% compared to the S&P 500's +10.3% gain over the past month.
Analysts maintain a Zacks Rank #3 (Hold) rating, suggesting limited confidence in strong outperformance relative to peers.
Charles River Laboratories (CRL), a leading provider of medical research equipment and services, is preparing to release quarterly earnings for the period ended March 2026 on May 7. Market consensus estimates project an EPS of $1.96, representing a 16.2% year-over-year decline from the previous quarter, with total revenues expected at $971.06 million, a slight decrease of 1.3%. The Zacks Consensus Estimate for CRL has been revised down by 4.84% over the last 30 days, reflecting analysts collectively reassessing their initial forecasts. Recent trends in estimate revisions suggest that covering analysts are becoming more bullish on the company, as the Most Accurate Estimate now exceeds the Consensus Estimate by 0.30%, resulting in a positive Earnings ESP of +0.30%.
According to Zacks Investment Research analysis, CRL currently holds a Zacks Rank of #3 (Hold). The research indicates that a combination of a positive Earnings ESP and a strong Zacks Rank typically predicts an earnings beat, as stocks with these attributes have produced positive surprises nearly 70% of the time. For context on CRL's historical performance, the company beat consensus estimates in all four trailing quarters, including a surprise of +2.58% in the most recently reported quarter where actual EPS of $2.39 exceeded expectations of $2.33. While an earnings beat is likely based on these metrics, investors are cautioned that stock price movements can also be influenced by management's discussion of business conditions and other factors that may disappoint investors regardless of financial results.
In related industry news, competitor Cencora (COR) is also set to report earnings for the same period ended March 2026, with expectations of $4.81 per share in EPS, up 8.8% year-over-year, and revenues projected at $80.76 billion, an increase of 7%. Although Cencora has a history of beating estimates across the last four quarters, its current Earnings ESP is -0.80%, and it carries a Zacks Rank of #4 (Sell), making it difficult to predict a definitive outcome based solely on these proprietary metrics. Analysts note that while betting on companies expected to beat earnings increases the odds of success, investors should utilize tools like the Zacks Earnings Calendar and consider both earnings expectations and Zacks Ranks when forming investment decisions ahead of quarterly releases.
📅 CRL releases Q1 2026 earnings on May 7 with projected EPS of $1.96 and revenue of $971M.
📉 Earnings estimates dropped 4.84%, though a positive ESP suggests analysts now favor an earnings beat.
🏆 CRL holds a Zacks Rank #3, historically beating consensus in four of its last five quarters.
👀 Investors should review the earnings call for management clues on long-term sustainability.
💼 Cencora contrasts with a Sell rank and negative ESP despite expected revenue growth this quarter.
- 📅 Charles River Laboratories (CRL) is scheduled to release its Q1 earnings report on May 7 for the quarter ended March 2026.
- 💸 The company is expected to report earnings of $1.96 per share, representing a year-over-year decline of 16.2%.
- 📉 Quarterly revenue is projected at $971.06 million, down 1.3% from the same quarter last year.
- 🔄 The consensus EPS estimate has been revised downward by 4.84% over the past 30 days.
- 🧠 Zacks analysis indicates a positive Earnings ESP of +0.30%, suggesting analysts are becoming more bullish recently.
- 🏆 CRL currently holds a Zacks Rank of #3 (Hold), which combined with a positive ESP points to a likely earnings beat.
- 📊 Historically, the company has beaten consensus EPS estimates in four out of the last five quarters.
- ⚠️ Past performance shows the stock beat expectations by 2.58% in the most recent reported quarter.
- 📈 Stock price movement may still vary due to other business factors regardless of whether a beat occurs.
- 🔎 Analysts are paying close attention to management's discussion on the earnings call for long-term sustainability clues.
- 👥 The Zacks model notes that negative ESP readings make it difficult to predict beats with confidence.
- 🆚 Cencora (COR) is also reporting earnings but faces a Sell rank and negative ESP of -0.80%.
- 💼 COR is expected to report EPS of $4.81 with revenue growing 7% to $80.76 billion for the quarter.
- 📅 Both companies will be featured in upcoming earnings announcements tracked by the Zacks Earnings Calendar.
- 🛠 Investors are encouraged to utilize the Zacks Earnings ESP Filter to identify potential buy or sell candidates before reports.
Bullish Signals
Analysts have recently become more bullish on Charles River's earnings prospects, raising the Most Accurate Estimate above the consensus level.
The company's Earnings ESP is positive at +0.30%, indicating a higher likelihood of beating earnings expectations based on the proprietary Zacks model.
Combined with a Zacks Rank of #3 (Hold), historical data suggests this combination produces an earnings beat nearly 70% of the time.
Charles River has a strong track record of exceeding estimates, having beaten consensus EPS in four out of the last four quarters reported.
The most recent quarter demonstrated a positive surprise history, with actual earnings of $2.39 per share exceeding expectations of $2.33 by +2.58%.
Risk Factors
Analysts have collectively revised the consensus EPS estimate for Charles River lower by 4.84% over the last 30 days, reflecting growing caution about near-term earnings.
The market consensus expects a year-over-year decline in earnings of -16.2%, indicating a significant negative sentiment regarding profitability growth.
Revenues are forecast to be $971.06 million, down 1.3% from the same quarter last year, suggesting potential revenue headwinds.
The company carries a Zacks Rank of #3 (Hold), which limits predictive power for an earnings beat and introduces uncertainty about stock price performance if results miss expectations.
A negative Earnings ESP reading is difficult to interpret as a guarantee of missing estimates, creating risk that the actual EPS will deviate from even the bullish 'Most Accurate Estimate'.
Following the reopening of the Strait of Hormuz, which signaled a cooling in global logistics and energy costs, several healthcare stocks including Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen experienced significant gains in the afternoon trading session on April 17. This market movement reflects a "risk-on" sentiment driven by the ceasefire news, as lower oil prices reduce operational expenses for large hospital facilities and aid in shipping sensitive medical equipment. The reduction in transportation overhead provides vital margin relief for a sector previously squeezed by high costs, fostering a more favorable outlook for quarterly earnings and encouraging investors to fund long-term R&D and clinical trials that had been constrained by macroeconomic uncertainty.
Specific stock movements highlight the impact of this broader economic stabilization on individual companies. Envista shares jumped 3.5%, while Baxter rallied 3.9%, Surgery Partners climbed 3.6%, Charles River Laboratories rose 3.7%, and Repligen advanced 3.4%. Analysts note that despite Baxter typically exhibiting low volatility with only eight moves greater than 5% in the past year, this particular increase suggests investors view the news as meaningful. The article contextualizes Baxter's recent performance by noting it has been down 4% since the start of the year and is trading at $18.72, which is 41.3% below its 52-week high of $31.88 set in May 2025. This downturn is partly attributed to disappointing second-quarter results nine months ago, where adjusted earnings per share of 59 cents missed estimates and revenue of $2.81 billion fell short of expectations due to lingering hurricane effects and supply disruptions.
The stabilization of the global economy ensures that elective procedures and pharmaceutical demand remain on a steady upward trajectory for the remainder of 2026, allowing high-growth biotech and pharmaceutical names to attract capital again. The article emphasizes that while stock markets often overreact to news, significant price drops can present buying opportunities for high-quality stocks. However, it also provides a historical perspective on Baxter's investment performance, noting that an investor who purchased $1,000 worth of shares five years ago would currently hold only $216.31. The piece concludes with broader market considerations, such as the volatility of Charles River Laboratories and questions regarding the duration of the AI boom, though it primarily focuses on how improved logistics costs and economic steadiness are reshaping sentiment in the healthcare sector.
🌍 Global markets rally on Strait of Hormuz reopening and cooling energy costs.
📈 Healthcare sector sees risk-on capital flow to biotech and pharmaceutical companies.
💉 Major healthcare stocks like Baxter gain significantly despite recent earnings misses.
🌍 Global stock markets rose in the afternoon session after the reopening of the Strait of Hormuz suggested cooling global logistics and energy costs.
🏥 Lower oil prices reduce operating expenses for healthcare facilities and shipping medical equipment, improving profit margins for the sector.
📈 A ceasefire-driven "risk-on" sentiment is encouraging capital to flow back into high-growth biotech and pharmaceutical companies.
🔁 Reduced market volatility is prompting investors to fund long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainty.
🔺 Envista (NVST) shares jumped 3.5% as a dental equipment and technology company benefiting from the market rebound.
💉 Baxter (BAX) shares climbed 3.9%, representing a notable move for a company historically characterized by low volatility.
🚑 Surgery Partners (SGRY) stock rose 3.6%, reflecting investor optimism in outpatient and specialty care providers.
🧪 Charles River Laboratories (CRL) gained 3.7% as a drug development inputs and services company sees renewed interest.
⚗️ Repligen (RGEN) shares increased 3.4%, marking another rise for a biotechnology manufacturing and process equipment provider.
📉 Baxter currently trades at $18.72 per share, which is down 4% year-to-date and approximately 41% below its 52-week high.
🌪️ Baxter recently reported adjusted earnings of 59 cents that missed estimates due to lingering effects of Hurricane Helene damaging a manufacturing facility.
📉 Revenue for Baxter stood at $2.81 billion, slightly below expectations, leading management to lower its full-year profit guidance.
📊 Historical context shows Baxter was the biggest move mentioned last year when it dropped 20% after disappointing second-quarter results nine months ago.
💡 Analysts suggest big price drops often present opportunities to buy high-quality stocks once market overreaction subsides.
⚠️ The article notes that while Baxter's recent jump may be meaningful given its low volatility, it might not fundamentally change investor perception of the business.
Bullish Signals
Charles River Laboratories jumped 3.7% in trading, reflecting positive investor sentiment following the reopening of the Strait of Hormuz.
Lower oil prices and cooling global logistics costs provide vital margin relief for healthcare providers and medical device manufacturers like Charles River Laboratories, allowing for a more favorable quarterly earnings outlook.
The 'risk-on' sentiment sparked by recent geopolitical stability is driving capital back into high-growth biotech and pharmaceutical names, benefiting companies like Charles River Laboratories.
As broader market volatility recedes, investors are increasingly willing to fund long-term R&D and clinical trials, ensuring a steady upward trajectory for demand in the remainder of 2026.
Big price drops can present significant buying opportunities for high-quality stocks like Charles River Laboratories as the market stabilizes.
Risk Factors
Baxter's adjusted earnings per share of 59 cents missed analysts' estimates, while revenue of $2.81 billion came in slightly below expectations.
The company lowered its full-year profit guidance due to lingering effects of Hurricane Helene which damaged a key manufacturing facility and disrupted the supply of IV solutions.
Management cited demand softness as a reason for the weak results and revised outlook, prompting a negative reaction from investors.
Baxter is down 4% since the beginning of the year and is trading 41.3% below its 52-week high of $31.88.
Investors who bought Baxter's shares 5 years ago would now be looking at only $216.31 for an initial $1,000 investment.
ClearBridge Investments, the manager of its Small Cap Growth Strategy, included Charles River Laboratories International (NYSE:CRL) as a newly acquired position in its first-quarter 2026 commentary. The Russell 2000 Growth Index declined by 2.8% during the quarter due to shifting technological and geopolitical narratives, yet the strategy outperformed its benchmark through strong stock selection in industrials and consumer staples. ClearBridge highlighted CRL as a leading preclinical contract research organization (CRO) that offers essential drug discovery, development, and safety testing services, positioning it to benefit from anticipated recoveries in preclinical research activity and biotech funding.
In the first quarter of 2026, Charles River Laboratories International's shares traded at $175.55 per share on April 9, delivering a one-month return of 12.92% and a 52-week gain of 75.99%. The company holds a market capitalization of $8.66 billion. ClearBridge noted that the firm added eight new portfolio ideas in total during the quarter, and CRL was among those additions, with the investment manager citing the company's integrated platform as a key advantage. The firm's scale allows it to capture disproportionate value as funding flows return to the biotechnology sector.
Hedge fund positioning data indicates that 53 portfolios held Charles River Laboratories International at the end of the fourth quarter of 2025, compared to 50 in the prior period. However, ClearBridge maintained a distinction between its growth strategy holdings and broader AI market themes, noting that while CRL represents a solid opportunity in healthcare, certain artificial intelligence stocks currently offer greater upside potential with lower downside risk according to their analysis. The commentary also directed readers toward separate reports on top hedge fund holdings for 2026 and additional articles covering other investor views on the biotechnology sector.
📉 Russell 2000 Growth Index dropped 2.8% in Q1 despite small-cap diversification outperformance.
🏢 ClearBridge Investments added Charles River Laboratories International to its Small Cap Growth portfolio.
🧪 CRL is a top preclinical research provider with $8.66B market cap and 76% annual gain.
💡 Management sees disproportionate upside as biotech funding and preclinical research activity recover.
📉 The Russell 2000 Growth Index declined 2.8% in Q1 2026 due to technological and geopolitical dynamics, though small-cap stocks overall outperformed via diversification into value-oriented sectors.
📊 ClearBridge Investments added Charles River Laboratories International (CRL) as a newly acquired position in its Small Cap Growth Strategy during Q1 2026.
🧪 CRL is identified as the leading preclinical contract research organization providing drug discovery and safety testing services to biopharma customers.
💰 The stock closed at $175.55 on April 9, 2026, delivering a one-month return of 12.92% and gaining 75.99% over the past 52 weeks.
📈 CRL has a market capitalization of $8.66 billion according to recent filings.
⚡ ClearBridge management notes that CRL's scale and integrated platform position it to benefit disproportionately as preclinical research activity and biotech funding recover.
🤝 Hedge Fund data indicates 53 portfolios held CRL at the end of Q4, an increase from 50 in the previous quarter.
⚠️ While acknowledging CRL's potential, the commentary suggests certain AI stocks offer greater upside potential with less downside risk for some investors.
🔗 The article references a broader market narrative regarding AI capital expenditure cycles influencing sector dispersion.
📢 Read next links promote reports on 33 stocks to double in three years and 15 stocks expected to increase wealth over a decade.
Bullish Signals
ClearBridge added Charles River as a new position.
Shares closed at $175.55, with 12.92% one-month return.
52-week gain reached 75.99%.
Market cap of $8.66 billion reflects sector significance.
Company leads preclinical CROs serving biopharmaceutical clients.
Hedge fund holdings rose from 50 to 53 portfolios.
Risk Factors
Stock excluded from top 40 hedge fund list.
Limited institutional interest versus AI peers.
ClearBridge sees greater upside in AI stocks than CRL.
CRL carries more downside risk than ClearBridge admits.
Only 53 hedge funds held stock at Q4 end of 2026.
Hedge fund accumulation was marginal quarter over quarter.
Commentary favors AI and tariff benefits over long-term value.
Competitive headwinds from capital pivot to AI infrastructure.
Valuation relies on unguaranteed biotech funding recovery.
Market focus on AI spending risks valuation stability.
Institutional sentiment remains cautious on CRL.
Bullish Signals
Charles River Laboratories International, Inc. (NYSE:CRL) was recently added as a new position by ClearBridge Small Cap Growth Strategy, indicating confidence in its growth potential.
The company closed at $175.55 per share on April 9, 2026, with a strong one-month return of 12.92% and a 52-week gain of 75.99%.
Charles River Laboratories International, Inc. has a market capitalization of $8.66 billion, reflecting its significant presence in the contract research organization sector.
The company is recognized as the leading preclinical CRO providing essential drug research services to biopharmaceutical customers.
Hedge fund interest is growing, with holdings increasing from 50 hedge fund portfolios in the previous quarter to 53 at the end of the fourth quarter.
Its scale and integrated platform position it to benefit disproportionately as preclinical research activity and biotech funding recover.
Risk Factors
The stock is not included in the list of 40 Most Popular Stocks Among Hedge Funds, suggesting limited institutional interest compared to other high-conviction AI plays.
ClearBridge explicitly states it believes certain AI stocks offer greater upside potential and carry less downside risk than Charles River Laboratories International, Inc. (NYSE:CRL).
Only 53 hedge fund portfolios held the stock at the end of Q4 2026 compared to just 50 in the previous quarter, indicating only marginal institutional accumulation.
The commentary is heavily weighted toward promoting AI stocks and short-term tariff benefits, implicitly downplaying CRL's long-term value proposition.
Charles River Laboratories International faces significant competitive headwinds as investors pivot capital toward artificial intelligence infrastructure rather than traditional preclinical research services.
The company's valuation relies on a recovery in biotech funding that is not guaranteed given the current market focus on AI expenditure cycles.
Institutional sentiment appears cautious, with ClearBridge explicitly ranking CRL below AI equities for risk-adjusted returns and upside potential.
Shares of Charles River Laboratories International Inc. (CRL) advanced 3.26% to $175.07 on Wednesday, marking a second consecutive day of gains for the stock. This performance occurred against a backdrop of strong broader market activity, with the S&P 500 Index rising 2.51% to 6,782.81 and the Dow Jones Industrial Average climbing 2.85% to 47,909.92. The stock's positive movement contributed to an overall strong trading session characterized by significant gains across major market indices.
The article highlights that this was a notably positive day for CRL, with shares outperforming competitors in the current market environment. However, the provided content primarily focuses on reporting these specific trading figures and the concurrent rise of major benchmarks like the S&P 500 and Dow Jones Industrial Average. The report includes standard data disclaimers noting that intraday data is delayed at least 15 minutes or subject to exchange requirements, while end-of-day historical data is sourced from FACTSET. All quotes in the article reflect trades reported through Nasdaq only during local exchange time.
MarketWatch Automation supported this reporting by leveraging world-class markets data from Dow Jones and FactSet, alongside a partnership with Automated Insights, to deliver timely and accurate content at record speed. The publication is dated April 8, 2026, and notes that the provided information reflects real-time last sale data subject to Nasdaq reporting standards. No further details regarding company-specific earnings, operational results, or future outlook for Charles River Laboratories International are included in the article text beyond these market performance metrics.
📈 Charles River stock rose 3.26% to $175.07, outperforming broader market gains.
🎯 Shares gained for a second consecutive day following prior positive trading.
📊 S&P 500 climbed 2.51% and Dow Jones increased 2.85% in wider context.
📈 Charles River Laboratories International Inc. stock rose 3.26% to $175.07 on Wednesday, outperforming broader market gains.
🎯 The stock achieved a second consecutive day of positive performance following the previous trading session.
📊 Market context saw the S&P 500 Index rise 2.51% to 6,782.81 and the Dow Jones Industrial Average increase 2.85% to 47,909.92.
Bullish Signals
CRL shares rose 3.26% to $175.07, outpacing rivals.
Stock gained for second straight day.
Risk Factors
No negative information identified.
Bullish Signals
Charles River Laboratories International Inc. (CRL) shares advanced 3.26% to $175.07, outperforming competitors on a strong trading day.
This marked the stock's second consecutive day of gains, demonstrating sustained investor interest and upward momentum.
Risk Factors
No negative information identified in the article.
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories stocks experienced declines in the afternoon session following the release of a proposed 2027 federal budget that included significant spending cuts for key health agencies. The budget request specifically targeted a reduction in funding for the Department of Health and Human Services (HHS), proposing a $5 billion cut for the National Institutes of Health (NIH). As the NIH is a critical source of funding for medical research, these reductions introduced uncertainty regarding innovation and development pipelines for pharmaceutical and biotech firms. While Congress is considered unlikely to approve the full extent of the proposed cuts, the proposal generated market volatility and price drops across the sector.
Among the affected companies, QuidelOrtho saw the largest decline with shares falling 6.4%, while Organon dropped 4.6%, Guardant Health fell 4%, Charles River Laboratories decreased by 3.6%, and Fortrea saw a 3.4% decrease. The market reaction to the budget news has been interpreted as an overreaction, potentially presenting buying opportunities for high-quality stocks. However, QuidelOrtho's shares are noted as extremely volatile, having experienced 42 moves greater than 5% over the last year. Analysts suggest that despite today's meaningful move, it does not necessarily indicate a fundamental change in perception of the company's business model.
In its recent performance, QuidelOrtho's shares have struggled significantly, dropping 44% since the beginning of the year. Currently trading at $16.13 per share, the stock is down 56.9% from its 52-week high of $37.42 reached in May 2025. Historical valuation context indicates that an investor who purchased $1,000 worth of QuidelOrtho shares five years ago would now hold a position valued at only $123.88. This decline follows previous market turbulence seen ten days ago when broader indices fell due to U.S.-Iran conflict concerns and policy deadlines under the Trump administration, which contributed to a sliding University of Michigan sentiment index that reached a three-month low.
📉 A proposed 2027 federal budget revealed significant spending cuts for health agencies, causing several biotech and pharmaceutical stocks to fall in the afternoon session.
🏥 The Department of Health and Human Services (HHS) funding reduction includes a specific proposal to cut National Institutes of Health (NIH) funding by $5 billion.
🔬 As a critical source of research funding, the proposed NIH cuts introduce uncertainty for pharmaceutical and biotech firms' innovation and development pipelines.
📈 While Congress is unlikely to approve the full extent of the cuts, the proposal created enough market uncertainty to trigger price drops in several key stocks.
🧬 Guardant Health (NASDAQ:GH) fell 4%, while Organon (NYSE:OGN) declined by 4.6%.
⚗️ Drug development inputs companies Fortrea (NASDAQ:FTRE) and Charles River Laboratories (NYSE:CRL) dropped 3.4% and 3.6% respectively.
🔍 Diagnostics firm QuidelOrtho (NASDAQ:QDEL) suffered the largest decline in the group, falling 6.4%.
📊 Market volatility analysis suggests that today's move for QuidelOrtho is meaningful but does not fundamentally alter investors' perception of the business.
📉 QuidelOrtho shares have experienced extreme volatility with 42 intraday moves greater than 5% over the past year.
💸 Since the start of the year, QuidelOrtho has been down 44%, trading significantly below its 52-week high of $37.42 from May 2025.
🌍 Previous market reactions were driven by geopolitical uncertainty tied to the U.S.-Iran conflict and policy deadlines set by the Trump administration.
📉 Consumer confidence has also declined, with the University of Michigan's sentiment index sliding to a three-month low due to fears of prolonged conflict.
Bullish Signals
Big price drops due to overreaction offer opportunities to buy high-quality stocks.
QuidelOrtho's volatility shows news isn't fundamentally damaging its business perception.
Charles River fell 3.6%, showing relative stability versus QuidelOrtho's 6.4% drop.
Healthcare stock uncertainty creates buying opportunities even without full budget cuts.
Risk Factors
$5B NIH cut proposal creates biotech uncertainty.
Market uncertainty drove several stocks down.
Guardant Health fell 4% on news.
Organon fell 4.6% on proposed cuts.
Fortrea declined 3.4% on sector impact.
QuidelOrtho dropped 6.4%, trading at $16.13.
Charles River Laboratories fell 3.6%.
QuidelOrtho volatile with 42 moves over 5%.
QuidelOrtho down 44% year-to-date.
Consumer confidence hurt by conflicts and oil prices.
Bullish Signals
The article suggests that big price drops due to market overreaction can present good opportunities to buy high-quality stocks.
QuidelOrtho's volatility indicates the market views recent news as meaningful but not fundamentally damaging to its business perception.
Despite a 44% drop year-to-date, QuidelOrtho remains trading below its 52-week high of $37.42 from May 2025, implying significant upside potential if sentiment improves.
Charles River Laboratories shares fell only 3.6%, indicating relative stability compared to peers like QuidelOrtho which dropped 6.4%.
The article highlights that while Congress is unlikely to approve full budget cuts, any uncertainty creates a buying opportunity for undervalued healthcare stocks.
Risk Factors
A proposed $5 billion cut for the National Institutes of Health (NIH) creates uncertainty for the biotech and pharmaceutical sectors, which could impact innovation and development pipelines.
Despite Congress being unlikely to approve the full extent of the cuts, the proposal has introduced market uncertainty that drove several stocks down in the afternoon session.
Guardant Health (NASDAQ:GH) fell 4% following the news.
Organon (NYSE:OGN) fell 4.6% in reaction to the proposed federal spending cuts.
Fortrea (NASDAQ:FTRE) declined by 3.4% as testing and diagnostics services stocks were negatively impacted.
QuidelOrtho (NASDAQ:QDEL) experienced a significant 6.4% decline, with shares trading at $16.13, which is 56.9% below its 52-week high of $37.42 from May 2025.
Charles River Laboratories (NYSE:CRL) fell 3.6% in the afternoon session.
QuidelOrtho's stock has been extremely volatile with 42 moves greater than 5% over the last year, raising concerns about price stability.
QuidelOrtho is down 44% since the beginning of the year, indicating sustained investor skepticism and capital erosion.
Prolonged conflicts and rising oil prices have negatively impacted consumer confidence, further complicating the outlook for healthcare spending.
Charles River Laboratories International Inc. (CRL) shares advanced 1.39% to $174.90 on Wednesday, marking the stock's third consecutive day of gains. Despite the positive daily performance, the company underperformed relative to its competitors during the session. The broader market remained strong on Wednesday, with the S&P 500 Index rising 0.72% to close at 6,575.32 and the Dow Jones Industrial Average gaining 0.48% to reach 46,565.74.
The news article highlights a contrast between CRL's individual stock movement and its peer group, noting that while the stock finished higher for the third day in a row, it failed to match the pace of other companies in its sector or the overall market momentum. The specific price level of $174.90 is presented against the backdrop of wider market indices reaching levels of 6,575.32 and 46,565.74 respectively.
The provided text also includes standard disclosures regarding data sources, noting that intraday data is supplied by FACTSET and real-time last sale data reflects trades reported through Nasdaq. A delay disclaimer indicates that intraday data may be delayed at least 15 minutes or more depending on exchange requirements. The content was published by MarketWatch on April 1, 2026, citing partnerships with Dow Jones and FactSet for world-class markets data support.
📈 CRIS shares rose 1.39% to $174.90, outpacing broader market gains.
🔄 Stock marks third consecutive day of consecutive daily increases.
📈 Charles River Laboratories International Inc. shares rose 1.39% to $174.90 on Wednesday, outpacing the broader market despite overall positive sentiment.
🤝 The stock's gain was part of a larger trading session where the S&P 500 climbed 0.72% and the Dow Jones Industrial Average advanced 0.48%.
🔄 This marked the third consecutive day that CRIS stock recorded gains following previous daily increases.
⚖️ Despite rising prices, CRIS stock underperformed compared to its sector competitors during Wednesday's trading session.
📊 Market data for the report was supported by Dow Jones and FactSet platforms providing intraday and historical exchange quotes.
ℹ️ The article notes that all quoted U.S. stock figures reflect trades reported through Nasdaq only with specific delay policies.
CNBC will debut an in-depth, one-hour special titled "CNBC Cures: Defying Rare Disease" on Thursday, March 19 at 7PM ET. Hosted by Becky Quick, the program will move beyond the anchor desk to explore her family's personal struggle with her daughter's rare disease, providing a human perspective on the challenges faced by patients navigating groundbreaking scientific advances versus persistent gaps in funding and access. The special is designed to spotlight families dealing with rare diseases alongside scientists, advocates, and innovators working to change their futures.
The program features exclusive interviews with prominent industry figures including GeneDx CEO Katherine Stueland, n-Lorem Founder & CEO Dr. Stanley Crooke, former FDA Commissioner Dr. Scott Gottlieb, Charles River Laboratories President & CEO Jim Foster, Biotechnology Innovation Organization President & CEO John Crowley, and Cure Rare Disease Founder & CEO Rich Horgan. In addition to these leaders, the special will include insights from physicians at the Children's Hospital of Philadelphia, Beast Games winner Jeffrey Allen, and various families navigating rare diseases who are actively advocating for their community.
CNBC promotes itself as a global leader in business and financial news reaching half a billion people monthly across platforms including live TV, CNBC.com, digital subscriptions like CNBC+ and CNBC Select, and mobile apps. The network describes its mission as helping business leaders and investors make informed decisions while covering real-time market data and breaking news from headquarters in the U.S., Europe, and Asia. The special will air on Thursday, March 19 at 7PM ET according to Eastern Time.
🎬 CNBC debuts one-hour special "CNBC Cures" March 19 exploring rare diseases.
👩💻 Hosted by Becky Quick, who shares personal family battle with rare disease.
🧬 Special spotlights innovators addressing gaps in funding and access for patients.
🎬 CNBC will debut a one-hour special titled "CNBC Cures: Defying Rare Disease" on Thursday, March 19 at 7PM ET.
👩💻 The program is hosted by Becky Quick, who shares her family's personal battle with her daughter's rare disease.
🧬 The special spotlights families affected by rare diseases and the innovators working to improve their futures.
💊 It highlights the gap between scientific advances and the ongoing issues of funding, access, and support for patients.
🗣️ Guests include GeneDx CEO Katherine Stueland, n-Lorem Founder Dr. Stanley Crooke, former FDA Commissioner Dr. Scott Gottlieb, and Biotechnology Innovation Organization President John Crowley.
🏥 Interviews also feature executives from Charles River Laboratories, Cure Rare Disease, physicians from the Children's Hospital of Philadelphia, and "Beast Games" winner Jeffrey Allen.
📺 CNBC is a global leader in business and financial news reaching half a billion people monthly across platforms.
💻 The network offers content through live TV, digital destinations like CNBC.com, and subscription services including CNBC+ and CNBC Pro.
📱 Audiences can access premium content via live events, podcasts, newsletters, and social media channels.
📩 CNBC is seeking confidential news tips from the public regarding rare disease developments.
Bullish Signals
Special premieres March 19 at 7PM ET covering rare disease innovation.
Becky Quick hosts interviews with industry leaders GeneDx CEO Stueland and FDA's Dr. Gottlieb.
CNBC reaches half a billion people monthly across all platforms.
Highlights innovators changing patient futures with scientific progress.
Audiences access premium content via CNBC+ digital destinations.
Risk Factors
Patients face a gap between science breakthroughs and persistent funding.
Access, support, and unresolved systemic challenges remain critical issues.
Rising capital expenditure may outpace available rare disease funding.
Bullish Signals
The special will premiere on Thursday, March 19 at 7PM ET, providing timely coverage of rare disease innovation.
Hosted by Becky Quick, the program features exclusive interviews with leading industry leaders including GeneDx CEO Katherine Stueland and former FDA Commissioner Dr. Scott Gottlieb.
CNBC reaches half a billion people every month across all platforms, offering broad reach for the in-depth reporting.
The special highlights innovators fighting to change patient futures, showcasing positive progress in scientific advances.
Audiences can access premium content through various CNBC+ and digital destinations to stay informed on market-moving forces.
Risk Factors
The special reveals stark reality of patients caught between groundbreaking scientific advances and persistent gaps in funding, access, and support, highlighting unresolved systemic challenges.
Rising capital expenditure in medical research may be outpacing available funding for rare disease treatments as noted by the stark reality described in the program.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
